Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma
Recruiting
N/A
Interventional Study
Glioblastoma, IDH-wildtype
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 120 (estimated)
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The study aims at:
1. Perform a multilayer analysis relying on tight integration of in-depth multi-omics approaches with clinical data to discover immune markers, with attention to age and sex differences, predicting prognosis and defining key life/environmental elements, to guide AI-driven personalised treatments and ensure improved care and QoL of glioblastoma patients.
2. To deepen glioblastom…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
To be enrolled in the study patients must:
1. Have a radiological diagnosis of supratentorial glioblastoma, or
2. Have a radiological diagnosis of first recurrence of a primary supratentorial glioblastoma (for which a formal histopathologic diagnosis of glioblastoma had made at…
Contacts
Quintino Giorgio D'Alessandris, MD, PhD
+39 06 30155414
quintinogiorgio.dalessandris@policlinicogemelli.it
CONTACT